HRAS and cancer: Remarkably, while enhanced MAPK1 activation associated with oncogenic mutations in upstream signal transducers (e.g., KRAS, HRAS, NRAS, and BRAF) is a common finding in cancer, MAPK1 mutations do not represent a major somatic event contributing to oncogenesis.